Nifty 50 · Healthcare
Sun Pharmaceutical
Sun Pharma is India's largest pharmaceutical company and a global leader in generic medicines.
SUNPHARMA · Healthcare
₹1,945.00
−6.00 (−0.31%)
Day High
₹1,957.00
Day Low
₹1,925.10
52W High
₹2,046.90
52W Low
₹1,548.00
Volume today: 24.25 L
PaisaTamil Consensus
BUYScore 73/100 · Medium confidence
Overall fundamentals and market signals are favourable. Consider for long-term portfolios with periodic review.
12M Price Target
₹2,140
Low ₹1,906 · High ₹2,431
Analyst-style Breakdown
Strong Buy
0
Buy
4
Hold
13
Sell
0
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum85/100
1M +3.0%, 1Y +22.8%
Earnings Trend80/100
Latest quarter revenue ₹15.2k Cr, profit ₹2.9k Cr
Valuation62/100
P/E 35.0x vs sector median ~35x
Financial Quality65/100
ROE 12.5%, ROCE 11.8%
Technical Position65/100
Trading between 52W low 1548 and high 2047
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹15.2k Cr | ₹2.9k Cr | ₹12.10 | +18.5% | +34.6% |
| Mar 2026 | ₹14.6k Cr | ₹2.7k Cr | ₹11.30 | — | — |
| Dec 2025 | ₹15.5k Cr | ₹3.4k Cr | ₹14.00 | — | — |
| Jun 2025 | ₹13.8k Cr | ₹2.3k Cr | ₹9.50 | — | — |
| Mar 2025 | ₹12.8k Cr | ₹2.1k Cr | ₹9.00 | — | — |
Key Ratios
Market Cap
₹3.8 L Cr
P/E Ratio
35.0x
P/B Ratio
4.8x
ROE
12.5%
ROCE
11.8%
Dividend Yield
0.9%
Reference fundamentals for analysis. Verify latest quarterly results before making investment decisions.
Company Overview
Sun Pharma manufactures and sells generic drugs, specialty medicines, and branded formulations across India, US, and emerging markets.
Strengths
- +Strong US generic and specialty pipeline
- +India chronic therapy market leadership
- +Improving margin profile
- +Debt reduction and cash generation
Risks
- −US FDA inspection and compliance risk
- −Price erosion in US generics
- −Currency impact on US revenue
- −Patent cliff on specialty products
Investment Analysis
What to watch
- • Sun Pharma is the bellwether for Indian pharma.
- • US specialty revenue growth is the key driver.
- • FDA compliance history matters for sentiment.
| Industry | Pharmaceuticals |
|---|---|
| Sector | Healthcare |
| NSE Symbol | SUNPHARMA |
| Index Weight | 2.10% |
| Market Cap | ₹3.8 L Cr |
Frequently Asked Questions
Yes. Sun Pharmaceutical is a current constituent of the Nifty 50, which means it is among the 50 largest and most liquid stocks on the National Stock Exchange (NSE).